Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ALLR Allarity Therapeutics Inc

Pre-Market Trading 06-24 09:19:07 EDT

0.4455

-0.0091

-2.00%

盘前0.3599

-0.0856-19.21%

09:18 EDT

High0.4699	Low0.4420	Vol4.79M
Open0.4505	D1 Closing0.4546	Amplitude6.14%
Mkt Cap7.84M	Tradable Cap7.84M	Total Shares17.61M
T/O2.16M	T/O Rate27.23%	Tradable Shares17.61M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ALLR","market":"US","secType":"STK","nameCN":"Allarity Therapeutics Inc","latestPrice":0.4455,"timestamp":1719000000000,"preClose":0.4546,"halted":0,"volume":4794971,"hourTrading":{"tag":"盘前","latestPrice":0.3599,"preClose":0.4455,"latestTime":"09:18 EDT","volume":181247,"amount":64943.78161315,"timestamp":1719235099890},"delay":0,"floatShares":17606594,"shares":17606739,"eps":-205.10883,"marketStatus":"Pre-Market Trading","change":-0.0091,"latestTime":"06-24 09:19:07 EDT","open":0.4505,"high":0.4699,"low":0.442,"amount":2164559.7142359,"amplitude":0.061373,"askPrice":0.36,"askSize":600,"bidPrice":0.357,"bidSize":2600,"shortable":3,"etf":0,"ttmEps":-205.10883,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1719235800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":0.4455,"preHourTrading":{"tag":"盘前","latestPrice":0.3599,"preClose":0.4455,"latestTime":"09:18 EDT","volume":181247,"amount":64943.78161315,"timestamp":1719235099890},"postHourTrading":{"tag":"盘后","latestPrice":0.361,"preClose":0.4455,"latestTime":"19:59 EDT","volume":4073990,"amount":1693909.842073,"timestamp":1719014397935},"volumeRatio":2.163885413868905},"requestUrl":"/m/hq/s/ALLR/wiki","defaultTab":"wiki","newsList":[{"id":"2441748489","title":"Allarity Therapeutics Signs New Management Services Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2441748489","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2441748489?lang=en_us&edition=fundamental","pubTime":"2024-06-06 22:02","pubTimestamp":1717682549,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics, Inc. (ALLR) just unveiled an update. Allarity Therapeutics, Inc. has transitioned from a consultancy agreement to a Manageme...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/allarity-therapeutics-signs-new-management-services-agreement?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/allarity-therapeutics-signs-new-management-services-agreement?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","ALLR","BK4139"],"gpt_icon":0},{"id":"2436915108","title":"BRIEF-Allarity Therapeutics Regains Compliance With Nasdaq's Minimum Stockholders' Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2436915108","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436915108?lang=en_us&edition=fundamental","pubTime":"2024-05-20 21:00","pubTimestamp":1716210024,"startTime":"0","endTime":"0","summary":"May 20 (Reuters) - Allarity Therapeutics Inc   :   * ALLARITY THERAPEUTICS REGAINS COMPLIANCE WITH NASDAQ'S MINIMUM STOCKHOLDERS' EQUITY REQUIREMENTSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210150020.SGD","QID","SQQQ","NQmain","BK4215","MNQmain","NDAQ","TQQQ","BK4585","QLD","LENZ",".IXIC","LU2095319765.USD","BK4112","LU2210149790.SGD","BK4588","BK4139","ALLR","EQR","QQQ","PSQ"],"gpt_icon":0},{"id":"2436179172","title":"Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2436179172","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2436179172?lang=en_us&edition=fundamental","pubTime":"2024-05-20 12:00","pubTimestamp":1716177600,"startTime":"0","endTime":"0","summary":"Boston (May 20, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/20/2884790/0/en/Allarity-Therapeutics-Regains-Compliance-with-Nasdaq-s-Minimum-Stockholders-Equity-Requirement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","NQmain",".IXIC","LU2095319765.USD","BK4139","BK4588","NDAQ","PSQ","SQQQ","MNQmain","BK4112","QQQ","QLD","LENZ","LU2210150020.SGD","BK4585","EQR","TQQQ","QID","BK4215","ALLR"],"gpt_icon":0},{"id":"2435528322","title":"Allarity Therapeutics Reports Clear Clinical Benefits From Phase 2 Trial; Improves Cash Balance Of $14M And Equity Balances Of $15M; Withdraws From S-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2435528322","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435528322?lang=en_us&edition=fundamental","pubTime":"2024-05-15 04:09","pubTimestamp":1715717365,"startTime":"0","endTime":"0","summary":"- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved- On Track to Regain Compliance with All Nasdaq Listing Requirements- No Variable Priced Securities are Outstanding- Warrant Overhang","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/general/biotech/24/05/38828167/allarity-therapeutics-reports-clear-clinical-benefits-from-phase-2-trial-improves-cash-balance-of","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","QID","TQQQ","QLD","BK4588","PSQ",".IXIC","MNQmain","SQQQ","QQQ","ALLR","BK4139","BK4215","EQR","NQmain","BK4585"],"gpt_icon":0},{"id":"2435254047","title":"Allarity Therapeutics Q1 EPS $(22.14)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435254047","media":"Benzinga","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435254047?lang=en_us&edition=fundamental","pubTime":"2024-05-15 04:06","pubTimestamp":1715717176,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics Q1 EPS $(22.14)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38827968/allarity-therapeutics-q1-eps-22-14","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ALLR","LENZ"],"gpt_icon":0},{"id":"2435540438","title":"Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances","url":"https://stock-news.laohu8.com/highlight/detail?id=2435540438","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2435540438?lang=en_us&edition=fundamental","pubTime":"2024-05-14 20:01","pubTimestamp":1715688060,"startTime":"0","endTime":"0","summary":"- Phase 2 Trial of Stenoparib Concluded Early due to Clear Clinical Benefits Achieved - On Track to Regain Compliance with All Nasdaq Listing Requirements - No Variable Priced Securities are Outstandi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/14/2881841/0/en/Allarity-Therapeutics-Reports-First-Quarter-Financial-Results-and-Highlights-including-Clear-Clinical-Benefits-from-Phase-2-Trial-NASDAQ-Compliance-and-Significant-Improvement-in-C.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NQmain","LU2210150020.SGD","BK4139","QID","QLD","TQQQ","LU2095319765.USD","BK4112","SQQQ","BK4588","PSQ","QQQ","BK4585","EQR",".IXIC","NDAQ","ALLR","MNQmain","LENZ","LU2210149790.SGD","BK4215"],"gpt_icon":0},{"id":"2434385015","title":"Allarity Therapeutics Restructures Capital and Reduces Debt","url":"https://stock-news.laohu8.com/highlight/detail?id=2434385015","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2434385015?lang=en_us&edition=fundamental","pubTime":"2024-05-09 22:03","pubTimestamp":1715263402,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics, Inc. (ALLR) has provided an announcement. Allarity Therapeutics, Inc. streamlined its capital structure by converting all ou...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/allarity-therapeutics-restructures-capital-and-reduces-debt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/allarity-therapeutics-restructures-capital-and-reduces-debt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALLR","BK4139","LENZ"],"gpt_icon":0},{"id":"2433973207","title":"Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2433973207","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433973207?lang=en_us&edition=fundamental","pubTime":"2024-05-07 13:30","pubTimestamp":1715059800,"startTime":"0","endTime":"0","summary":"- Conversions Eliminate All Variable Priced Derivative Securities - Conversions Eliminate Any Market Overhang from Warrants - Series A Preferred and Warrant Conversions were Investor Initiated - Limit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/07/2876853/0/en/Allarity-Therapeutics-Announces-that-All-Series-A-Preferred-and-All-Variable-Priced-Warrants-have-Converted-to-Common-Stock.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LENZ","ALLR"],"gpt_icon":1},{"id":"2433479778","title":"Allarity Therapeutics Anticipates Nasdaq Compliance, Withdraws S-1 Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2433479778","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433479778?lang=en_us&edition=fundamental","pubTime":"2024-05-06 21:42","pubTimestamp":1715002950,"startTime":"0","endTime":"0","summary":"An announcement from Allarity Therapeutics, Inc. (ALLR) is now available. Allarity Therapeutics, Inc. announced it expects to regain compliance wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/allarity-therapeutics-anticipates-nasdaq-compliance-withdraws-s-1-filing?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/allarity-therapeutics-anticipates-nasdaq-compliance-withdraws-s-1-filing?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4112","SQQQ","LU2210150020.SGD","LU2210149790.SGD","BK4585","MNQmain","QQQ","LENZ","TQQQ","QID",".IXIC","NDAQ","QLD","PSQ","LU2095319765.USD","BK4588","NQmain","BK4139","ALLR"],"gpt_icon":0},{"id":"2433424203","title":"Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1","url":"https://stock-news.laohu8.com/highlight/detail?id=2433424203","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2433424203?lang=en_us&edition=fundamental","pubTime":"2024-05-06 12:00","pubTimestamp":1714968000,"startTime":"0","endTime":"0","summary":"- Stockholders’ equity significantly surpasses the $2.5 million minimum required by Nasdaq - Company is to seek Nasdaq’s formal confirmation of compliance with equity requirements under the exchange’s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/06/2875731/0/en/Allarity-Therapeutics-Exceeds-Nasdaq-s-Minimum-Equity-Requirement-Requests-Voluntarily-Withdrawal-of-Form-S-1.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","QQQ","NDAQ",".IXIC","LU2210149790.SGD","NQmain","ALLR","LU2095319765.USD","QID","BK4112","LU2210150020.SGD","QLD","TQQQ","BK4588","PSQ","MNQmain","EQR","BK4215","BK4139","SQQQ","LENZ"],"gpt_icon":1},{"id":"2432903966","title":"AEON Biopharma, Allarity Therapeutics, ModivCare among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2432903966","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432903966?lang=en_us&edition=fundamental","pubTime":"2024-05-03 22:00","pubTimestamp":1714744837,"startTime":"0","endTime":"0","summary":"Gainers: Tandem Diabetes Care  +26%. Twist Bioscience  +25%. Healthcare Triangle  +23%. ModivCare  +21%. Alignment Healthcare  +20%.  Losers: AEON Biopharma  -54%. Owens & Minor  -18%. Allarity Therapeutics  -9%. Cardiff Oncology  -7%. DaVita  -6%.  S&P 500 Health Care Sector +0.31% to 1641.82. Health Care Equipment & Services +0.1% to 1900.03. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is +0.51% to 1348.24.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4099713-aeon-biopharma-allarity-therapeutics-modivcare-among-healthcare-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["SDS","BK4559","BK4539","BK4196","BK4585","OMI","TNDM","ALHC","BK4550",".SPX","VOO","SPY","BK4581","AEON","IVV","OEF","ALLR","HCTI","BK4167","BK4534","UPRO","MODV","BK4175","CRDF","SPXU","SH","ALLR.AU","BK4588","BK4082","BK4154","SSO","TWST","DVA","BK4504","LENZ","BK4139","ESmain","OEX"],"gpt_icon":0},{"id":"2432092495","title":"Allarity Therapeutics’ Stenoparib Shows Promise in Ovarian Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2432092495","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432092495?lang=en_us&edition=fundamental","pubTime":"2024-05-03 18:22","pubTimestamp":1714731762,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics, Inc. (ALLR) has provided an announcement. Allarity Therapeutics, Inc. has announced a significant breakthrough with its drug...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/allarity-therapeutics-stenoparib-shows-promise-in-ovarian-cancer-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/allarity-therapeutics-stenoparib-shows-promise-in-ovarian-cancer-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","ALLR"],"gpt_icon":0},{"id":"2432602351","title":"CytomX Therapeutics, Allarity Therapeutics, Pulmonx among healthcare movers","url":"https://stock-news.laohu8.com/highlight/detail?id=2432602351","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432602351?lang=en_us&edition=fundamental","pubTime":"2024-05-02 22:00","pubTimestamp":1714658443,"startTime":"0","endTime":"0","summary":"Gainers: Allarity Therapeutics  +107%. Emergent Biosolutions  +66%. Pulmonx  +26%. Context Therapeutics  +25%. Lantheus Holdings  +17%.  Losers: Accuray  -21%. Metagenomi  -16%. Atricure  -16%. CytomX Therapeutics  -12%. Elevation Oncology  -12%.  S&P 500 Health Care Sector -0.21% to 1635.09. Health Care Equipment & Services -0.15% to 1889.78. Pharmaceuticals, Biotechnology & Life Science which contributes 58% to index is -0.27% to 1343.2.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098640-cytomx-therapeutics-allarity-therapeutics-pulmonx-among-healthcare-movers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["OEX","SPXU","BK4198","SDS","ELEV","MGX","MGX.AU","BK4585","ESmain","BK4581","CTMX","LNTH",".SPX","SH","OEF","BK4539","UPRO","BK4550","BK4559","SSO","BK4583","BK7129","ALLR.AU","LUNG","BK7509","BK4588","EBS","BK4504","BK4082","VOO","SPY","CNTX","ARAY","BK4534","BK4139","ATRC","BK4007","IVV","ALLR"],"gpt_icon":0},{"id":"2432605513","title":"Allarity rallies on conclusion of mid-stage trial for its ovarian cancer treatment after showing clinical benefit","url":"https://stock-news.laohu8.com/highlight/detail?id=2432605513","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432605513?lang=en_us&edition=fundamental","pubTime":"2024-05-02 21:01","pubTimestamp":1714654899,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics  shares up more than double premarket after it announced the early discontinuation of its Phase 2 clinical trial of stenoparib, a novel PARP inhibitor, for the treatment of advanced recurrent ovarian cancer as it showed clear clinical benefit.  The trial, evaluating stenoparib given twice daily, has shown clear clinical benefit, including tumor shrinkage and long-term disease stability, in heavily pre-treated ovarian cancer patients who otherwise have limited life expectancy. These results have provided sufficient clinical proof of concept for stenoparib as monotherapy, prompting Allarity to halt further enrollment in this trial to enable and accelerate the development of a follow-on trial with FDA regulatory intent. This company’s decision will not affect the ongoing treatment of current patients, as described in greater detail in Allarity’s March 27, 2024, press release. Source: Press Release","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098498-allarity-rallies-on-conclusion-of-mid-stage-trial-for-its-ovarian-cancer-treatment-after-showing-clinical-benefit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ALLR","BK4139"],"gpt_icon":0},{"id":"2432608733","title":"NOVA, STI and SGMT are among premarket gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2432608733","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432608733?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:43","pubTimestamp":1714653794,"startTime":"0","endTime":"0","summary":"Gainers: Allarity Therapeutics  +133% Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer.  Emergent Biosolutions  +54% gains as results top estimates, co to cut 300 jobs.  Carvana  +37% rips a 35% gains after J.P. Morgan upgrade adds to the earnings buzz  Context Therapeutics  +35% stock jumps on $100M private placement.  Aspen Aerogels  +30% Q1 earnings call release  Enovix Corporation  +29% q1 earnings call release  Pulmonx  +23% Q1 earnings call release  Wayfair  +19% Q1 earnings call release  Sagimet Biosciences  +17%. Rush Street Interactive  +15% Q1 earnings call release  Peloton Interactive  +13% Q3 earnings call release  Organogenesis Holdings  +12% Achieves Primary Endpoint in Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis.  Bon Natural Life  +11%. Solidion Technology  +11%. Sunnova Energy International  +11% Q1 earnings call release","market":"hk","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/522334235/image_522334235.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4098484-nova-sti-and-sgmt-are-among-premarket-gainers","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["SGMT","EBS","STI.SI","ASPN","BK4548","BK4178","RSI","BK4539","BK4150","BK4532","CVNA","BK4566","BK4190","BK4524","ALLR.AU","BK4585","BK4503","BK4082","ORGO","ALLR","STI","BON","BK4007","BK4583","BK4588","BK4551","BK4096","BK4214","BK4179","LUNG","PTON","BK4561","ENVX","CNTX","W","BK4198","BK4122","BK4139","BK4109"],"gpt_icon":0},{"id":"2432677172","title":"BRIEF-Allarity Therapeutics' Stenoparib Sees Early Conclusion Of Phase 2 Trial In Advanced Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2432677172","media":"Reuters","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432677172?lang=en_us&edition=fundamental","pubTime":"2024-05-02 20:12","pubTimestamp":1714651975,"startTime":"0","endTime":"0","summary":"May 2  - Allarity Therapeutics Inc   :   * ALLARITY THERAPEUTICS’ STENOPARIB SHOWS CLEAR CLINICAL BENEFIT AND ACHIEVES SIGNIFICANT MILESTONE WITH EARLY CONCLUSION OF PHASE 2 TRIAL IN ADVANCED OVARIAN CANCERSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4157","IE0031619046.USD","BK4139","LENZ","IE00B66KJ199.SGD","IE00B19Z4B17.USD","AEIS","IE00B7SZL793.SGD","ALLR"],"gpt_icon":0},{"id":"2432672583","title":"Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2432672583","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2432672583?lang=en_us&edition=fundamental","pubTime":"2024-05-02 12:00","pubTimestamp":1714622400,"startTime":"0","endTime":"0","summary":"Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today ann","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/05/02/2874113/0/en/Allarity-Therapeutics-Stenoparib-Shows-Clear-Clinical-Benefit-and-Achieves-Significant-Milestone-with-Early-Conclusion-of-Phase-2-Trial-in-Advanced-Ovarian-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4157","IE00B7SZL793.SGD","LENZ","BK4139","IE00B19Z4B17.USD","ALLR","IE00B66KJ199.SGD","IE0031619046.USD","AEIS"],"gpt_icon":0},{"id":"2431234183","title":"Allarity Therapeutics Maintains NASDAQ Compliance with Bid Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2431234183","media":"TIPRANKS","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431234183?lang=en_us&edition=fundamental","pubTime":"2024-04-30 20:23","pubTimestamp":1714479794,"startTime":"0","endTime":"0","summary":"An update from Allarity Therapeutics, Inc. (ALLR) is now available. Allarity Therapeutics, Inc. has announced that they have successfully met NASDA...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/allarity-therapeutics-maintains-nasdaq-compliance-with-bid-price?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/allarity-therapeutics-maintains-nasdaq-compliance-with-bid-price?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","QQQ","NDAQ",".IXIC","LU2210149790.SGD","NQmain","ALLR","LU2095319765.USD","QID","BK4112","LU2210150020.SGD","QLD","TQQQ","BK4588","PSQ","MNQmain","BK4139","SQQQ","LENZ"],"gpt_icon":0},{"id":"2431863270","title":"Allarity regains compliance with NASDAQ minimum bid price requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2431863270","media":"seekingalpha","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431863270?lang=en_us&edition=fundamental","pubTime":"2024-04-29 21:21","pubTimestamp":1714396900,"startTime":"0","endTime":"0","summary":"Allarity Therapeutics  hasreceived a notice which confirms that the Co. has regained compliance with the minimum bid price requirement as set forth in Nasdaq’s Listing Rule.Nasdaq noted that since April 9, 2024, Allarity’s stock has maintained a closing bid price above $1/share for more than ten consecutive trading days, thereby meeting the requirements for regaining compliance.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4095478-allarity-regains-compliance-with-nasdaq-minimum-bid-price-requirement","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU2095319765.USD","LU2210150020.SGD","QID","NDAQ","BK4112","NQmain","BK4585","BK4588","LU2210149790.SGD","QLD","TQQQ","BK4139","SQQQ","ALLR",".IXIC","QQQ","PSQ","MNQmain"],"gpt_icon":0},{"id":"2431346348","title":"Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement","url":"https://stock-news.laohu8.com/highlight/detail?id=2431346348","media":"GlobeNewswire","labels":[],"top":-1,"share":"https://ttm.financial/m/news/2431346348?lang=en_us&edition=fundamental","pubTime":"2024-04-29 11:00","pubTimestamp":1714359600,"startTime":"0","endTime":"0","summary":"Boston (April 29, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, toda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/04/29/2871065/0/en/Allarity-Therapeutics-Regains-Compliance-with-NASDAQ-Minimum-Bid-Price-Requirement.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SQQQ","LU2210150020.SGD","LU2210149790.SGD","BK4585","MNQmain","QQQ","LENZ","TQQQ","QID",".IXIC","NDAQ","QLD","PSQ","LU2095319765.USD","BK4588","NQmain","BK4139","ALLR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.allarity.com","stockEarnings":[{"period":"1week","weight":-0.0207},{"period":"1month","weight":-0.3039},{"period":"3month","weight":-0.9365},{"period":"6month","weight":-0.9607},{"period":"1year","weight":-0.9969},{"period":"ytd","weight":-0.9596}],"compareEarnings":[{"period":"1week","weight":0.0032},{"period":"1month","weight":0.0277},{"period":"3month","weight":0.0447},{"period":"6month","weight":0.1496},{"period":"1year","weight":0.2474},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. Allarity Therapeutics, Inc. has a collaboration with Detsamma Investments Pty. Ltd. to develop Deflexifol for the treatment of solid tumors. The company was incorporated in 2004 and is headquartered in Boston, Massachusetts.","exchange":"NASDAQ","name":"Allarity Therapeutics Inc","nameEN":"Allarity Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.1","shortVersion":"4.24.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Allarity Therapeutics Inc(ALLR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Allarity Therapeutics Inc,ALLR,Allarity Therapeutics Inc股票,Allarity Therapeutics Inc股票老虎,Allarity Therapeutics Inc股票老虎国际,Allarity Therapeutics Inc行情,Allarity Therapeutics Inc股票行情,Allarity Therapeutics Inc股价,Allarity Therapeutics Inc股市,Allarity Therapeutics Inc股票价格,Allarity Therapeutics Inc股票交易,Allarity Therapeutics Inc股票购买,Allarity Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Allarity Therapeutics Inc(ALLR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Allarity Therapeutics Inc(ALLR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}